Breast Cancer Research Partnership 2016

Dr Tracy Hale
Massey University
Funder(s): HRC, Breast Cancer Cure, The New Zealand Breast Cancer Foundation
Targeting HP1 regulated pathways to suppress breast cell invasion
24 months

Lay summary

Metastasis is the primary cause of death in breast cancer patients as it refractory to current therapies. The first step in metastatic disease occurs when a cell invades surrounding tissue. However, before a cell can invade, its nucleus must become malleable enough to ensure the cell can squeeze through the local tissue matrix. The requirement for nuclear reorganisation at this critical stage provides a unique opportunity to prevent metastasis by targeting the key pathways involved.

Heterochromatin Protein 1a (HP1a) maintains the highly condensed portion of the genome and tethers it to the nuclear membrane. We propose the loss of HP1a that is commonly observed in invasive breast tumours is responsible for the changes in nuclear architecture that lead to increased nuclear malleability in these cells. Therefore, by exploring nuclear remodelling pathways regulated by HP1a, we will reveal potential new drug targets for therapy of metastatic breast disease.

Back to Funding Recipients